Immunotherapy in Xeroderma Pigmentosum: a case of advanced cutaneous squamous cell carcinoma treated with cemiplimab and a literature review.
advanced squamous cell carcinoma
cemiplimab
hadrontherapy
immunotherapy
xeroderma pigmentosum
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
25 May 2021
25 May 2021
Historique:
received:
04
01
2021
accepted:
03
05
2021
entrez:
4
6
2021
pubmed:
5
6
2021
medline:
5
6
2021
Statut:
epublish
Résumé
Xeroderma Pigmentosum (XP) is a rare genetic disorder with a poor prognosis due to high photosensitivity in affected patients. Herein, we describe the first case of the use of cemiplimab in a patient with XP, a 19-year-old girl presented with locally advanced squamous cell carcinoma of the right periorbital and nasal region. This treatment has been undertaken after a cycle of proton beam radiotherapy. Besides, it is reported a description of the few cases in the literature describing the effectiveness of immunotherapy on skin cancers in XP-patients. This case is in line with those reported, underlining how anti-PD1 monoclonal antibodies may be a promising treatment in this genodermatosis.
Identifiants
pubmed: 34084285
doi: 10.18632/oncotarget.27966
pii: 27966
pmc: PMC8169062
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1116-1121Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright: © 2021 Rubatto et al.
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST Authors have no conflicts of interest to declare.
Références
JCO Precis Oncol. 2019 Sep 20;3:
pubmed: 32923855
Br J Dermatol. 2019 Nov;181(5):1095-1097
pubmed: 31102460
Br J Dermatol. 2018 May;178(5):1199-1203
pubmed: 29274233
Hum Vaccin Immunother. 2016 Nov;12(11):2777-2789
pubmed: 27398650
Cold Spring Harb Mol Case Stud. 2019 Oct 23;5(5):
pubmed: 31645345
Pediatr Blood Cancer. 2018 Feb;65(2):
pubmed: 28988442
Eur J Cancer. 2017 Sep;83:99-102
pubmed: 28734147
Head Neck Pathol. 2016 Jun;10(2):139-44
pubmed: 26975629
Anticancer Res. 2019 Sep;39(9):4613-4617
pubmed: 31519558
Mol Cancer Ther. 2017 Nov;16(11):2598-2608
pubmed: 28835386
Arch Dermatol. 1987 Feb;123(2):241-50
pubmed: 3545087
Drugs. 2018 Nov;78(17):1841-1846
pubmed: 30456447
J Med Genet. 2011 Mar;48(3):168-76
pubmed: 21097776
Eur J Cancer. 2017 May;77:84-87
pubmed: 28365530